Hui Zheng

Hui Zheng

Auto-generated profile, based on publicly available information

Hui Zheng

Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangdong-Hong Kong Joint Laboratory for Stem Cell and Regenerative Medicine, GIBH-CUHK Joint Research Laboratory on Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2013 in Nature Cell Biology
Verified
Journal Article
Closed access
XLXiaopeng Liu
Xiaopeng Liu
HSHao Sun
Hao Sun
JQJing Qi
Jing Qi
LWLinli Wang
Linli Wang
SHSongwei He
Songwei He
HZHui Zheng
Hui Zheng

21 June 2006 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
GPGuangjin Pan
Guangjin Pan
JLJun Li
Jun Li
YZYali Zhou
Yali Zhou
HZHui Zheng
Hui Zheng
DPDuanqing Pei
Duanqing Pei
Embryonic stem (ES) cells possess the ability to renew themselves while maintaining the capacity to differentiate into virtually all cell types of the body. Current evidence suggests that ES cells maintain their pluripotent state by expressing a battery of transcription factors including Oct4 and Nanog. However, little is known about how ES cells maintain the expression of these pluripotent factors in ES cells. Here we present evidence that Oct4, Nanog, and FoxD3 form a negative feedback loop to maintain their expression in pluripotent ES cells. First, Oct4 maintains Nanog activity by directly activating its promoter at sub‐steady‐state concentration but repressing it at or above steady‐state levels. On the other hand, FoxD3 behaves as a positive activator of Nanog to counter the repressive effect of Oct4. The expression of Oct4 is activated by FoxD3 and Nanog but repressed by Oct4 itself, thus, exerting an important negative feedback loop to limit its own activity. Indeed, overexpression of either FoxD3 or Nanog in ES cells failed to increase the concentration of Oct4 beyond the steady‐state concentration, whereas knocking down either FoxD3 or Nanog reduces the expression of Oct4 in ES cells. Finally, overexpression of Oct4 or Nanog failed to compensate the loss of Nanog or Oct4, respectively, suggesting that both are required for ES self‐renewal and pluripotency. Our results suggest the FoxD3‐Nanog‐Oct4 loop anchors an interdependent network of transcription factors that regulate stem cell pluripotency.—Pan, G., Li, J., Zhou, Y., Zheng, H., Pei, D. A negative feedback loop of transcription factors that controls stem cell pluripotency and self‐renewal. FASEB J. 20, E1094–E1102 (2006)

1 January 2008 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
HZHui Zheng
Hui Zheng
HLHorace H. Loh
Horace H. Loh
PLPing-Yee Law
Ping-Yee Law
The cellular location of extracellular signal-regulated kinases (ERKs) activated by a G protein-coupled receptor was shown to be dependent on the pathway that mediated their activation. In general, fast activation of ERKs (2 min) mediated by G proteins resulted in the nuclear translocation of phosphorylated ERKs, whereas a slower activation of ERKs (10 min) mediated by β-arrestins resulted in the cytosolic retention of the phosphorylated ERKs. However, we observed distinct differences from this established ERKs cellular itinerary with the μ-opioid receptor-activated ERKs. Agonists such as morphine and methadone activated ERKs via the protein kinase C-dependent pathway but not the β-arrestin-dependent pathway. The activated ERKs did not translocate into the nucleus, but phosphorylated 90-kDa ribosomal S6 kinase and induced the activity of transcription factor cAMP response element-binding protein. In contrast, agonists such as etorphine and fentanyl activated ERKs in a β-arrestin-dependent manner. The phosphorylated ERKs translocated into the nucleus, resulting in increases in Elk-1 activity and GRK2 and β-arrestin2 transcriptions. Thus, the cellular location of phosphorylated ERKs and subsequent activities on gene transcriptions are dictated by the agonist used to activate the receptor and the subsequent signaling pathway involved.

6 August 2020 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
XLXiaowei Lai
Xiaowei Lai
QLQian Li
Qian Li
FWFang Wu
Fang Wu
JLJiechun Lin
Jiechun Lin
JCJiekai Chen
Jiekai Chen
LGLin Guo
Lin Guo
Epithelial-mesenchymal transition (EMT) and its critical roles during cancer progression have long been recognized and extensively reviewed. Recent studies on the generation of induced pluripotent stem cells (iPSCs) have established the connections among EMT, energy metabolism, DNA methylation, and histone modification. Since energy metabolism, DNA methylation, and histone modification are important for cancer development and there are common characteristics between cancer cells and stem cells, it is reasonable to identify mechanisms that have been established during both reprogramming and cancer progression. In the current review, we start from a brief review on EMT and related processes during cancer progression, and then switch to the EMT during somatic cell reprogramming. We summarize the connection between EMT and metabolic switch during reprogramming, and further review the involvements of DNA methylation and cell proliferation. The connections between EMT and mesenchymal-epithelial transition (MET) and cellular aspects including DNA methylation, histone modification and energy metabolism may provide potential new targets for cancer diagnosis and treatment.

19 March 2012 in BMC Cell Biology
Verified
Journal Article
Open access
PDF file
HZHui Zheng
Hui Zheng
EPElizabeth A Pearsall
Elizabeth A Pearsall
DHDow P Hurst
Dow P Hurst
YZYuhan Zhang
Yuhan Zhang
JCJi Chu
Ji Chu
PLPing-Yee Law
Ping-Yee Law
A cholesterol-palmitoyl interaction has been reported to occur in the dimeric interface of the β2-adrenergic receptor crystal structure. We sought to investigate whether a similar phenomenon could be observed with μ-opioid receptor (OPRM1), and if so, to assess the role of cholesterol in this class of G protein-coupled receptor (GPCR) signaling.

1 January 2010 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
HZHui Zheng
Hui Zheng
YZYan Zeng
Yan Zeng
XZXiaoxiao Zhang
Xiaoxiao Zhang
JCJi Chu
Ji Chu
HLHorace H. Loh
Horace H. Loh
PLPing-Yee Law
Ping-Yee Law
The agonists of μ-opioid receptor (OPRM1) induce extracellular signal-regulated kinase (ERK) phosphorylation through different pathways: morphine uses the protein kinase C (PKC)-pathway, whereas fentanyl functions in a β-arrestin2-dependent manner. In addition, the two pathways result in the different cellular location of phosphorylated ERK and the activation of different sets of transcriptional factors. In the current study, the influence of the two pathways on the expression of microRNAs (miRNAs) was investigated. After treating the primary culture of rat hippocampal neurons and the mouse hippocampi with morphine or fentanyl for 3 days, seven miRNAs regulated by one or two of the agonists were identified. One of the identified miRNAs, miR-190, was down-regulated by fentanyl but not by morphine. This down-regulation was attenuated by 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126), which blocks the phosphorylation of ERK. When fentanyl-induced but not morphine-induced ERK phosphorylation was blocked in the primary cultures from β-arrestin2(−/−) mouse, fentanyl did not decrease the expression of miR-190. However, a PKC inhibitor that blocked morphine-induced ERK phosphorylation specifically had no effect on the miR-190 down-regulation. Therefore the decrease in miR-190 expression resulted from the agonist-selective ERK phosphorylation. In addition, the expressional changes in one of the miR-190 targets, neurogenic differentiation 1 (NeuroD), correlated with those in miR-190 expression, suggesting the OPRM1 could regulate the NeuroD pathways via the control of miR-190 expression.